Low-density lipoprotein apheresis ameliorates monthly estimated glomerular filtration rate declines in patients with renal cholesterol crystal embolism

• Published in: Journal of artificial organs Vol. 18; no. 1; pp. 72 - 78
• Main Authors: Hirai, Keiji, Ookawara, Susumu, Miyazawa, Haruhisa, Ito, Kiyonori, Ueda, Yuichirou, Kaku, Yoshio, Hoshino, Taro, Yoshida, Izumi, Tabei, Kaoru
• Format: Journal Article
• Language: English
• Published: Tokyo Springer Japan 01.03.2015; Springer Nature B.V
• Subjects: Aged; Aged, 80 and over; Biomedical Engineering and Bioengineering; Blood Component Removal - methods; Cardiac Surgery; Embolism, Cholesterol - physiopathology; Embolism, Cholesterol - therapy; Female; Glomerular Filtration Rate - physiology; Humans; Kidney Failure, Chronic - physiopathology; Kidney Failure, Chronic - therapy; Male; Medicine; Medicine & Public Health; Middle Aged; Nephrology; Original Article; Treatment Outcome; LDL apheresis; eGFR; Cholesterol crystal embolism; Renal dysfunction
• ISSN: 1434-7229; 1619-0904
• DOI: 10.1007/s10047-014-0801-1

The incidence of cholesterol crystal embolism (CCE) has increased along with increases in the prevalence of atheromatous diseases and intravascular procedures. CCE frequently results in the deterioration of renal function, which sometimes leads to end-stage renal failure. Although there has been no established therapy for CCE, the possibility that low-density lipoprotein apheresis (LDL-A) is an effective therapy for renal CCE was previously reported. However, whether LDL-A improves renal CCE remains uncertain. This study aimed to evaluate the effectiveness of LDL-A in renal CCE patients. Twelve renal CCE patients (9 men and 3 women, mean age 70.6 ± 1.7 years) were included in this retrospective study. All patients had received LDL-A therapy, and estimated glomerular filtration rate (eGFR) values were examined before and after LDL-A. In addition, monthly changes in eGFR before and after LDL-A were calculated for each patient. At initial diagnosis of renal CCE, the eGFR was 35.2 ± 4.8 mL/min/1.73 m 2 . At the initiation of LDL-A, the eGFR significantly decreased to 11.0 ± 1.2 mL/min/1.73 m 2 , and monthly changes in eGFR reached −7.2 ± 2.5 mL/min/1.73 m 2 /month. After the initiation of LDL-A, the progression of renal dysfunction stabilized in nearly two-thirds of patients, and monthly changes in eGFR after LDL-A significantly diminished to −0.3 ± 0.7 mL/min/1.73 m 2 /month ( p  < 0.05 vs. before LDL-A). Although 4 patients had to undergo hemodialysis, all patients were alive over 1 year after the initiation of LDL-A. LDL-A therapy ameliorated renal dysfunction in renal CCE patients.